Alterity Therapeutics Limited (ATH.AX)
AUD 0.01
(-12.5%)
AUD 0.01
(-12.5%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 5.42 Million AUD | 20.44% |
| 2023 | 4.5 Million AUD | -23.57% |
| 2022 | 5.89 Million AUD | 89.2% |
| 2021 | 3.11 Million AUD | 13.0% |
| 2020 | 2.75 Million AUD | -17.83% |
| 2019 | 3.35 Million AUD | 26.86% |
| 2018 | 2.64 Million AUD | 66.25% |
| 2017 | 1.59 Million AUD | -32.53% |
| 2016 | 2.35 Million AUD | -13.35% |
| 2015 | 2.72 Million AUD | -31.19% |
| 2014 | 3.95 Million AUD | 27.6% |
| 2013 | 3.09 Million AUD | 80.35% |
| 2012 | 1.71 Million AUD | -17.37% |
| 2011 | 2.07 Million AUD | 32.29% |
| 2010 | 1.57 Million AUD | 85.51% |
| 2009 | 847.43 Thousand AUD | -53.84% |
| 2008 | 1.83 Million AUD | -12.97% |
| 2007 | 2.1 Million AUD | 24.62% |
| 2006 | 1.69 Million AUD | -36.93% |
| 2005 | 2.68 Million AUD | -0.46% |
| 2004 | 2.69 Million AUD | 377.62% |
| 2003 | 564.54 Thousand AUD | -38.15% |
| 2002 | 912.81 Thousand AUD | 2.04% |
| 2001 | 894.58 Thousand AUD | 507.99% |
| 2000 | 147.13 Thousand AUD | -92.33% |
| 1999 | 1.91 Million AUD | 859.02% |
| 1998 | 199.95 Thousand AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 4.56 Million AUD | 0.0% |
| 2024 Q4 | 5.42 Million AUD | 0.0% |
| 2024 FY | 5.42 Million AUD | 20.44% |
| 2023 FY | 4.5 Million AUD | -23.57% |
| 2023 Q4 | 4.5 Million AUD | 0.0% |
| 2023 Q2 | 5.27 Million AUD | 0.0% |
| 2022 Q2 | 3.8 Million AUD | 0.0% |
| 2022 FY | 5.89 Million AUD | 89.2% |
| 2022 Q4 | 5.89 Million AUD | 0.0% |
| 2021 FY | 3.11 Million AUD | 13.0% |
| 2021 Q4 | 3.11 Million AUD | 0.0% |
| 2021 Q2 | 3.05 Million AUD | 0.0% |
| 2020 Q2 | 3.28 Million AUD | 1.48% |
| 2020 Q3 | 2.71 Million AUD | -17.44% |
| 2020 Q4 | 2.75 Million AUD | 1.56% |
| 2020 FY | 2.75 Million AUD | -17.83% |
| 2020 Q1 | 3.24 Million AUD | -3.43% |
| 2019 Q1 | 3.22 Million AUD | 21.79% |
| 2019 Q3 | 3.32 Million AUD | 3.03% |
| 2019 Q2 | 3.22 Million AUD | 0.04% |
| 2019 FY | 3.35 Million AUD | 26.86% |
| 2019 Q4 | 3.35 Million AUD | 1.05% |
| 2018 Q3 | 2.64 Million AUD | 45.63% |
| 2018 Q2 | 1.81 Million AUD | 0.03% |
| 2018 Q1 | 1.81 Million AUD | 14.08% |
| 2018 FY | 2.64 Million AUD | 66.25% |
| 2018 Q4 | 2.64 Million AUD | 0.03% |
| 2017 Q1 | 2.84 Million AUD | 20.88% |
| 2017 Q2 | 2.84 Million AUD | 0.02% |
| 2017 FY | 1.59 Million AUD | -32.53% |
| 2017 Q4 | 1.59 Million AUD | 0.03% |
| 2017 Q3 | 1.59 Million AUD | -44.19% |
| 2016 Q3 | 2.35 Million AUD | 0.27% |
| 2016 Q4 | 2.35 Million AUD | 0.0% |
| 2016 FY | 2.35 Million AUD | -13.35% |
| 2016 Q2 | 2.35 Million AUD | 0.03% |
| 2016 Q1 | 2.35 Million AUD | -13.63% |
| 2015 Q2 | 3.29 Million AUD | 0.2% |
| 2015 Q3 | 2.71 Million AUD | -17.56% |
| 2015 FY | 2.72 Million AUD | -31.19% |
| 2015 Q4 | 2.72 Million AUD | 0.09% |
| 2015 Q1 | 3.29 Million AUD | -16.77% |
| 2014 Q3 | 3.95 Million AUD | -16.49% |
| 2014 Q2 | 4.73 Million AUD | 0.01% |
| 2014 Q4 | 3.95 Million AUD | 0.08% |
| 2014 FY | 3.95 Million AUD | 27.6% |
| 2014 Q1 | 4.73 Million AUD | 52.66% |
| 2013 Q3 | 3.09 Million AUD | -7.39% |
| 2013 FY | 3.09 Million AUD | 80.35% |
| 2013 Q4 | 3.09 Million AUD | 0.0% |
| 2013 Q2 | 3.34 Million AUD | 0.0% |
| 2013 Q1 | 3.34 Million AUD | 94.74% |
| 2012 FY | 1.71 Million AUD | -17.37% |
| 2012 Q4 | 1.71 Million AUD | 0.0% |
| 2012 Q2 | 2.07 Million AUD | 0.0% |
| 2011 Q2 | 1.1 Million AUD | 0.0% |
| 2011 FY | 2.07 Million AUD | 32.29% |
| 2011 Q4 | 2.07 Million AUD | 0.0% |
| 2010 Q2 | 962.69 Thousand AUD | 0.0% |
| 2010 FY | 1.57 Million AUD | 85.51% |
| 2010 Q4 | 1.57 Million AUD | 0.0% |
| 2009 Q4 | 847.43 Thousand AUD | 0.0% |
| 2009 FY | 847.43 Thousand AUD | -53.84% |
| 2009 Q2 | 2.13 Million AUD | 0.0% |
| 2008 Q2 | 4.22 Million AUD | 0.0% |
| 2008 Q4 | 1.83 Million AUD | 0.0% |
| 2008 FY | 1.83 Million AUD | -12.97% |
| 2007 Q2 | 3.81 Million AUD | 0.0% |
| 2007 Q4 | 2.1 Million AUD | 0.0% |
| 2007 FY | 2.1 Million AUD | 24.62% |
| 2006 Q2 | 1.19 Million AUD | 0.0% |
| 2006 FY | 1.69 Million AUD | -36.93% |
| 2006 Q4 | 1.69 Million AUD | 0.0% |
| 2005 Q4 | 2.68 Million AUD | 0.0% |
| 2005 Q2 | 1.47 Million AUD | 0.0% |
| 2005 FY | 2.68 Million AUD | -0.46% |
| 2004 FY | 2.69 Million AUD | 377.62% |
| 2004 Q4 | 2.69 Million AUD | 0.0% |
| 2004 Q2 | 1.68 Million AUD | 0.0% |
| 2003 Q4 | 564.54 Thousand AUD | 0.0% |
| 2003 FY | 564.54 Thousand AUD | -38.15% |
| 2003 Q2 | 1.15 Million AUD | 0.0% |
| 2002 FY | 912.81 Thousand AUD | 2.04% |
| 2001 FY | 894.58 Thousand AUD | 507.99% |
| 2000 FY | 147.13 Thousand AUD | -92.33% |
| 1999 FY | 1.91 Million AUD | 859.02% |
| 1998 FY | 199.95 Thousand AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AdAlta Limited | 3.54 Million AUD | -53.157% |
| Biome Australia Limited | 5.37 Million AUD | -0.976% |
| Radiopharm Theranostics Limited | 44.68 Million AUD | 87.857% |
| Biotron Limited | 737.5 Thousand AUD | -635.678% |
| Acrux Limited | 5.68 Million AUD | 4.595% |
| Botanix Pharmaceuticals Limited | 3.73 Million AUD | -45.38% |
| BTC Health Limited | 203.94 Thousand AUD | -2560.328% |
| Chimeric Therapeutics Limited | 12.8 Million AUD | 57.622% |
| CSL Limited | 27.88 Billion AUD | 99.981% |
| Clarity Pharmaceuticals Ltd | 8.33 Million AUD | 34.879% |
| Clinuvel Pharmaceuticals Limited | 28.11 Million AUD | 80.7% |
| Immutep Limited | 10.97 Million AUD | 50.584% |
| Memphasys Limited | 5.59 Million AUD | 2.981% |
| Neuren Pharmaceuticals Limited | 42.76 Million AUD | 87.312% |
| Noxopharm Limited | 1.28 Million AUD | -321.048% |
| Prescient Therapeutics Limited | 2.32 Million AUD | -133.306% |
| Race Oncology Limited | 1.91 Million AUD | -183.115% |
| Starpharma Holdings Limited | 8.69 Million AUD | 37.621% |
| Tissue Repair Ltd | 1.35 Million AUD | -301.634% |
| EZZ Life Science Holdings Limited | 4.22 Million AUD | -28.293% |
| Anatara Lifesciences Ltd | 306.84 Thousand AUD | -1668.194% |
| Bio-Gene Technology Limited | 368.44 Thousand AUD | -1372.586% |
| Zelira Therapeutics Limited | 9.35 Million AUD | 42.012% |
| Patrys Limited | 691.36 Thousand AUD | -684.779% |
| Orthocell Limited | 22.08 Million AUD | 75.43% |
| Imugene Limited | 33.14 Million AUD | 83.63% |
| PYC Therapeutics Limited | 10.18 Million AUD | 46.724% |
| Proteomics International Laboratories Limited | 1.62 Million AUD | -233.698% |
| Cynata Therapeutics Limited | 1.17 Million AUD | -363.316% |
| Arovella Therapeutics Limited | 2.05 Million AUD | -163.814% |
| Nanollose Limited | 465.64 Thousand AUD | -1065.203% |
| Invex Therapeutics Ltd | 431.63 Thousand AUD | -1157.022% |
| NeuroScientific Biopharmaceuticals Limited | 85.68 Thousand AUD | -6232.278% |
| Amplia Therapeutics Limited | 3.42 Million AUD | -58.331% |
| Island Pharmaceuticals Limited | 1.04 Million AUD | -418.895% |
| Nyrada Inc. | 855.63 Thousand AUD | -534.114% |
| Telix Pharmaceuticals Limited | 249.39 Million AUD | 97.824% |
| Dimerix Limited | 13.89 Million AUD | 60.947% |
| PharmAust Limited | 896.6 Thousand AUD | -505.135% |
| Hexima Limited | 248.67 Thousand AUD | -2081.882% |
| AnteoTech Limited | 4.07 Million AUD | -33.137% |
| Paradigm Biopharmaceuticals Limited | 3.58 Million AUD | -51.372% |
| Recce Pharmaceuticals Ltd | 15.89 Million AUD | 65.862% |
| Avecho Biotechnology Limited | 941.54 Thousand AUD | -476.257% |
| Actinogen Medical Limited | 1.61 Million AUD | -235.879% |
| Immuron Limited | 2.84 Million AUD | -91.01% |
| Argenica Therapeutics Limited | 2.42 Million AUD | -123.581% |